カテゴリ： GlobalData, 企業調査, 日本

Chugai Pharmaceutical Co Ltd (4519)-製薬・医療分野：企業M&A・提携分析

◆英語タイトル：Chugai Pharmaceutical Co Ltd (4519) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA8012224
◆発行会社（調査会社）：GlobalData
◆発行日：2017年12月14日
◆ページ数：106
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：日本
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single UserUSD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Chugai Pharmaceutical Co Ltd (Chugai), a subsidiary of Hoffmann-La Roche Ltd, is a provider of biopharmaceuticals and therapeutic antibodies. The company offers products for the treatment of cancer; bone and joint diseases; renal diseases; immunology and infectious diseases and others. It also offers drugs to aid kidney, liver and other organ transplantations. Chugai’s major products include Avastin (bevacizumab), Herceptin (trastuzumab), Rituxan (rituximab), Actemra (tocilizumab), Edirol (eldecalcitol) and Mircera (epoetin beta pegol). It also has a range of product candidates in its pipeline. The company offers its pharmaceutical products in overseas markets including North America, Europe and Asia. Chugai is headquartered in Tokyo, Japan.

Chugai Pharmaceutical Co Ltd (4519) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 6
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 8
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 9
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 10
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 11
Chugai Pharmaceutical Co Ltd, Medical Devices Deals, 2011 to YTD 2017 13
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 14
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deal Details 17
Partnerships 17
Helsinn Enters into Licensing Agreement with Chugai Pharma for Netupitant-Palonosetron Fixed-Dose Combination 17
Chugai Pharma Enters into Research Agreement with National Cancer Center Japan 18
Astellas Pharm, Kyowa Hakko Kirin, Daiichi Sankyo, Eisai, Ono Pharma and Chugai Pharma to Enter into Agreemet with Four Research Institutions 19
Chugai Pharmaceutical Enters into Agreement with Osaka University 21
Chugai Pharma Enters Into Co-Development Agreement With Nippon Shinyaku For GA101 22
Schnell BioPharma Enters Into Co-Development Agreement With Aprogen And Chunggei Pharm 23
Licensing Agreements 24
JW Pharma Enters into Licensing Agreement with Chugai Pharma 24
Chugai Pharma Enters into Licensing Agreement with SBI Pharma 25
Chugai Pharma Enters into Licensing Agreement with Pharma Mar 26
Berlin-Chemie Enters into Licensing Agreement with Chugai Pharma 27
Roche Enters into Licensing Agreement with Chugai Pharma for Recycling Antibody SA237 28
Chugai Pharma Enters into Licensing Agreement with Two Cells 29
BioMarin Pharma Enters into Sub-license Agreement with Chugai Pharma 30
PharmaMar Enters into Licensing Agreement with Chugai Pharma for Aplidin 31
Chugai Pharma Enters into Licensing Agreement with Roche 32
Maruho Enters into Licensing Agreement with Chugai Pharma 33
Galderma Pharma to Enter into Licensing Agreement with Chugai Pharma 34
Kowa Company Enters into Licensing Agreement with Chugai Pharmaceutical 35
EpiVax Enters into Licensing Agreement with Chugai Pharma 36
Roche Amends Licensing Agreement with Chugai Pharma 37
Helsinn Enters Into Licensing Agreement With Chugai Pharma Marketing For Anamorelin 38
Chugai Pharma Enters Into Licensing Agreement With Debiopharm Group For FF284 39
Chugai Pharma Expands Licensing Agreement with Kowa for DEBERZA 40
Chugai Pharma Extends Licensing Agreement With Genedata For Genedata Expressionist Software 41
Chugai Pharma Enters Into Licensing Agreement With Roche For MetMAb And Lebrikizumab 42
Chugai Pharma Enters Into Licensing Agreement With Roche For Vemurafenib 43
Asset Transactions 44
Taiyo Pharma to Acquire Product Rights from Chugai Pharma and Roche 44
Eisai Acquires Rights to Manufacture Active Pharmaceutical Ingredients in Japan from Chugai Pharma and F. Hoffman-La Roche 45
Acquisition 46
Roche May Acquire 40% Stake in Chugai Pharma 46
Chugai Pharmaceutical Co Ltd – Key Competitors 47
Chugai Pharmaceutical Co Ltd – Key Employees 48
Chugai Pharmaceutical Co Ltd – Locations And Subsidiaries 50
Head Office 50
Other Locations & Subsidiaries 50
Joint Venture 52
Recent Developments 53
Strategy And Business Planning 53
Jan 27, 2017: Aiming to Provide Solutions that Meet Changes of Regional Healthcare Services 53
Government and Public Interest 54
Mar 30, 2017: Chugai – ASTAR Joint Development Project for Anti-Dengue Virus Antibody Selected as Grant Recipient by the GHIT Fund 54
Product News 55
12/15/2016: Roche Receives CHMP Positive Opinion for Alecensa 55
12/01/2016: Tocilizumab to be listed on Australian Pharmaceutical Benefits Scheme 56
11/30/2016: Filing for Approval of “Actemra” for Additional Indication of “Large Vessel Vasculitis,” the Designated Intractable Disease 57
10/31/2016: Health Canada approves ALECENSARO – a targeted oral treatment – for patients with aggressive and rare form of lung cancer 58
10/13/2017: CHMP recommends EU approval of Roche’s Alecensa (alectinib) as a first-line treatment for people with ALK-positive NSCLC 60
10/04/2016: US FDA grants Breakthrough Therapy Designation for Roche’s Alecensa (alectinib) for first-line treatment of people with ALK-positive NSCLC 61
10/04/2016: FDA Grants Breakthrough Therapy Designation for Genentech’s Actemra (Tocilizumab) in Giant Cell Arteritis, a Form of Vasculitis 63
08/31/2016: ACTEMRA Subcutaneous Injection Wins a Prize at the JAPAN PACKAGING CONTEST 2016 65
08/10/2017: Announcement of Commencement of Arbitration against Chugai 66
06/26/2017: Approval of Additional Dosage for “Actemra Subcutaneous Injection” Reducing Dose Interval to One Week in Patients with Rheumatoid Arthritis Who Inadequately Respond to Bi-weekly Dose 67
05/22/2017: FDA approves first drug to specifically treat giant cell arteritis 68
04/04/2017: NICE Terminates Appraisal for Alectinib in Previously Treated ALK-positive Advanced NSCLC 69
02/27/2017: Chugai’s ALK Inhibitor “Alecensa” Approved in Taiwan 70
02/21/2017: Roche receives EU approval of Alecensa (alectinib) for people with previously treated ALK-positive non-small cell lung cancer 71
01/06/2016: NIHR: New treatment approach for Pulmonary Arterial Hypertension being tested 73
Product Approvals 74
Sep 01, 2017: Roche and MHRA to make treatment available for those newly diagnosed with a rare type of lung cancer in the UK before anywhere else in Europe 74
May 08, 2017: Roche’s Alecensa Rejects For Use Within NHS Scotland 75
Jan 23, 2017: FDA Grants Priority Review For Genentech’s Actemra (Tocilizumab) Supplemental Biologics License Application For Giant Cell Arteritis, a Form of Vasculitis 76
Aug 25, 2016: Application for Approval of Additional Dosage for “Actemra Subcutaneous Injection” in Patients with Rheumatoid Arthritis Who Inadequately Respond to Every Other Week Dosage 77
Mar 17, 2016: Chugai receives Orphan Drug Designation for Tocilizumab in Systemic Scleroderma 78
Clinical Trials 79
Sep 06, 2017: Roche presents data from global phase III study showing significant clinical benefit of Alecensa (alectinib) in later-line advanced ALK-positive lung cancer 79
Aug 09, 2017: Genentech Completes Phase III Enrollment for Study of Actemra in Systemic Sclerosis 80
Aug 02, 2017: FDA Grants Genentech’s Alecensa Priority Review for Initial Treatment of People with ALK-Positive Lung Cancer 81
Jul 26, 2017: Positive Phase III Results of Genentech’s Actemra (Tocilizumab) for the Treatment of Giant Cell Arteritis Published in New England Journal of Medicine 83
Jul 21, 2017: Roche Gains Positive CHMP Opinion for Actemra / Roactemra in Giant Cell Arteritis 85
Jun 06, 2017: Alectinib potential new standard of care for ALK-positive non-small lung cancer 86
Jun 05, 2017: Phase III study showed Roche’s Alecensa (alectinib) reduced the risk of disease progression or death by more than half versus crizotinib as first-line treatment in a specific type of lung cancer 87
May 11, 2017: Results of the J-ALEX Study for Chugais Alecensa are Published in The Lancet Online 89
Apr 10, 2017: Phase III study shows Roche’s Alecensa was superior to crizotinib in a specific type of lung cancer 90
Apr 03, 2017: Phase III ALUR study supports the use of Roche’s Alecensa for people with advanced ALK-positive lung cancer 91
Mar 02, 2017: Chugai’s Anti-IL-31 Receptor A Humanized Monoclonal Antibody “nemolizumab (CIM331)” Global Phase II Study Data Published in The New England Journal of Medicine Online 93
Feb 08, 2017: Roche’s Alecensa (alectinib) approved in Switzerland for people with a specific type of lung cancer 94
Nov 12, 2016: Phase III GiACTA study shows Roches Actemra/RoActemra is superior to steroids alone in maintaining steroid-free remission for people with giant cell arteritis 96
Nov 02, 2016: Roche to present new data on Actemra/RoActemra at the 2016 ACR/ARHP Annual Meeting 98
Jun 06, 2016: Phase III study shows Roche’s Actemra/RoActemra maintained steroid-free remission in people with Giant Cell Arteritis (GCA) 100
May 18, 2016: Phase III Study of Genentech’s Alecensa (Alectinib) Showed Superior Efficacy Versus Crizotinib in Japanese People With a Specific Type of Lung Cancer 101
May 16, 2016: Efficacy of Actemra Subcutaneous Injection Confirmed in Dose Interval Reduction Study in Patients with Rheumatoid Arthritis Who Inadequately Respond to Bi-weekly Dose 102
Mar 05, 2016: Chugai Announces Phase II Global Study Results of Nemolizumab (CIM331) in Late-breaking Research Forums at AAD 103
Feb 10, 2016: Chugai ALK Inhibitor Alecensa Trial Stopped Early for Benefit 104
Other Significant Developments 105
Apr 04, 2017: A First Approach in the Japanese Pharmaceutical Industry Starting a Trial of a Drug Adherence Support App Using Multidisciplinary SNS for Outpatient Cancer Treatment 105
Appendix 106
Methodology 106
About GlobalData 106
Contact Us 106
Disclaimer 106

List of Tables
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 8
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 9
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 10
Chugai Pharmaceutical Co Ltd, Deals By Therapy Area, 2011 to YTD 2017 11
Chugai Pharmaceutical Co Ltd, Medical Devices Deals, 2011 to YTD 2017 13
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 14
Helsinn Enters into Licensing Agreement with Chugai Pharma for Netupitant-Palonosetron Fixed-Dose Combination 17
Chugai Pharma Enters into Research Agreement with National Cancer Center Japan 18
Astellas Pharm, Kyowa Hakko Kirin, Daiichi Sankyo, Eisai, Ono Pharma and Chugai Pharma to Enter into Agreemet with Four Research Institutions 19
Chugai Pharmaceutical Enters into Agreement with Osaka University 21
Chugai Pharma Enters Into Co-Development Agreement With Nippon Shinyaku For GA101 22
Schnell BioPharma Enters Into Co-Development Agreement With Aprogen And Chunggei Pharm 23
JW Pharma Enters into Licensing Agreement with Chugai Pharma 24
Chugai Pharma Enters into Licensing Agreement with SBI Pharma 25
Chugai Pharma Enters into Licensing Agreement with Pharma Mar 26
Berlin-Chemie Enters into Licensing Agreement with Chugai Pharma 27
Roche Enters into Licensing Agreement with Chugai Pharma for Recycling Antibody SA237 28
Chugai Pharma Enters into Licensing Agreement with Two Cells 29
BioMarin Pharma Enters into Sub-license Agreement with Chugai Pharma 30
PharmaMar Enters into Licensing Agreement with Chugai Pharma for Aplidin 31
Chugai Pharma Enters into Licensing Agreement with Roche 32
Maruho Enters into Licensing Agreement with Chugai Pharma 33
Galderma Pharma to Enter into Licensing Agreement with Chugai Pharma 34
Kowa Company Enters into Licensing Agreement with Chugai Pharmaceutical 35
EpiVax Enters into Licensing Agreement with Chugai Pharma 36
Roche Amends Licensing Agreement with Chugai Pharma 37
Helsinn Enters Into Licensing Agreement With Chugai Pharma Marketing For Anamorelin 38
Chugai Pharma Enters Into Licensing Agreement With Debiopharm Group For FF284 39
Chugai Pharma Expands Licensing Agreement with Kowa for DEBERZA 40
Chugai Pharma Extends Licensing Agreement With Genedata For Genedata Expressionist Software 41
Chugai Pharma Enters Into Licensing Agreement With Roche For MetMAb And Lebrikizumab 42
Chugai Pharma Enters Into Licensing Agreement With Roche For Vemurafenib 43
Taiyo Pharma to Acquire Product Rights from Chugai Pharma and Roche 44
Eisai Acquires Rights to Manufacture Active Pharmaceutical Ingredients in Japan from Chugai Pharma and F. Hoffman-La Roche 45
Roche May Acquire 40% Stake in Chugai Pharma 46
Chugai Pharmaceutical Co Ltd, Key Competitors 47
Chugai Pharmaceutical Co Ltd, Key Employees 48
Chugai Pharmaceutical Co Ltd, Other Locations 50
Chugai Pharmaceutical Co Ltd, Subsidiaries 51
Chugai Pharmaceutical Co Ltd, Joint Venture 52

★海外企業調査レポート[Chugai Pharmaceutical Co Ltd (4519)-製薬・医療分野：企業M&A・提携分析]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Acesur：企業の戦略・SWOT・財務情報
    Acesur - Strategy, SWOT and Corporate Finance Report Summary Acesur - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, prov …
  • C&C Group plc：企業の戦略・SWOT・財務分析
    C&C Group plc - Strategy, SWOT and Corporate Finance Report Summary C&C Group plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • NuStar Energy LP (NS)：石油・ガス：M&Aディール及び事業提携情報
    Summary NuStar Energy LP (NuStar Energy) is a midstream oil and gas company. It carries out the transportation, terminalling, storage and marketing of petroleum products, and anhydrous ammonia. The company owns and operates pipelines, terminal and storage facilities that store and distribute crude o …
  • Huesker Synthetic GmbH：企業の戦略・SWOT・財務情報
    Huesker Synthetic GmbH - Strategy, SWOT and Corporate Finance Report Summary Huesker Synthetic GmbH - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Essel Propack Limited：戦略・SWOT・企業財務分析
    Essel Propack Limited - Strategy, SWOT and Corporate Finance Report Summary Essel Propack Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • North Asia Strategic Holdings Limited
    North Asia Strategic Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary North Asia Strategic Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analy …
  • Rizal Commercial Banking Corp (RCB)：電力：M&Aディール及び事業提携情報
    Summary Rizal Commercial Banking Corp (RCBC) is a commercial and financial banking service provider that offers corporate, commercial, and consumer banking, cash management, treasury, and remittance products and services. The company’s electronic banking services include mobile banking, internet ban …
  • RayBiotech Inc-医療機器分野：企業M&A・提携分析
    Summary RayBiotech Inc (RayBiotech) is a life science company that offers proteins, antibodies and immunological kits. The company’s products include antibody arrays, elisa, functional assays, antibodies and custom recombinant protein service. It provides services such as testing services, custom se …
  • Xcel Energy Inc (XEL)：電力：M&Aディール及び事業提携情報
    Summary Xcel Energy Inc. (Xcel Energy) is a vertically-integrated energy utility that generates, procures, transmits, distributes and sells electricity; and transports, stores and distributes natural gas through its subsidiaries. The company owns and operates generation assets utilizing diverse fuel …
  • Honda Motor Co., Ltd.：企業の戦略・SWOT・財務情報
    Honda Motor Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Honda Motor Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Fraport Slovenija, d.o.o.：企業の戦略・SWOT・財務情報
    Fraport Slovenija, d.o.o. - Strategy, SWOT and Corporate Finance Report Summary Fraport Slovenija, d.o.o. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Stentys SA (STNT)：企業の財務・戦略的SWOT分析
    Summary Stentys SA (Stentys) is a medical device company that designs, develops and markets self-expanding stents for the treatment of patients with acute myocardial infarction and coronary disease. The company’s products include xposition S self-applying stent, mistent biodegradable sirolimus relea …
  • CK Infrastructure Holdings Ltd (1038)：企業の財務・戦略的SWOT分析
    CK Infrastructure Holdings Ltd (1038) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths an …
  • SCHOTT AG：企業の戦略・SWOT・財務情報
    SCHOTT AG - Strategy, SWOT and Corporate Finance Report Summary SCHOTT AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Coca-Cola HBC AG：企業の戦略・SWOT・財務情報
    Coca-Cola HBC AG - Strategy, SWOT and Corporate Finance Report Summary Coca-Cola HBC AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • s.a. D’leteren n.v.：企業の戦略・SWOT・財務情報
    s.a. D'leteren n.v. - Strategy, SWOT and Corporate Finance Report Summary s.a. D'leteren n.v. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Therapeutic Solutions International Inc (TSOI)：医療機器：M&Aディール及び事業提携情報
    Summary Therapeutic Solutions International Inc (Therapeutic Solutions) is a pharmaceutical company that offers supplements. The company offers products such as DermalStilbene, NanoStilbene and ProJuvenol. Its ProJuvenol consists of anti-aging ingredients which helps for a healthy functionality for …
  • Triskalia：戦略・SWOT・企業財務分析
    Triskalia - Strategy, SWOT and Corporate Finance Report Summary Triskalia - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • PVA TePla AG (TPE)：企業の財務・戦略的SWOT分析
    PVA TePla AG (TPE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • HealthCare Global Enterprises Ltd (HCG)：企業の財務・戦略的SWOT分析
    Summary HealthCare Global Enterprises Ltd (HCG), formerly Curie Centre of Oncology Private Ltd is a healthcare service provider that provides medical care and treatment services. The company provides services such as clinical laboratory services, diagnosis services, medical oncology services, radiat …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆